Funny how there has not been the marketing push reported in Singapore like there was in Europe or the states (if any at all) , and the application for early access was reportedly initiated by the surgeons. The good news must be filtering out there. Singaporean surgeons attending the recent scientific meetings in the states and Europe perhaps hearing about it and wanting to give it a go. Suggests that cardiocel will ultimately sell it self. If Billcans numbers are accurate (4-5 centres across Singapore) it is a massive uptake (heading towards acceptance) by the majority of clinicians in the country. Now that is exciting.
Ann: CardioCel gains special access in Singapore, page-38
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.22 |
Change
0.740(6.45%) |
Mkt cap ! $258.3M | |||
| Open | High | Low | Value | Volume |
| $11.50 | $12.25 | $11.49 | $395.2K | 33.29K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100 | $11.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.22 | 127 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |